UKPDS findings show that raised HbA1c levels increase the risk of serious complications17
Relationship between risk of diabetic complications and mean HbA1c9:
Prompt management of HbA1c levels may prevent or delay long-term T2DM complications and as a result is likely to result in cost savings6,8
The UK Prospective Diabetes Study Group (UKPDS) showed a 1% reduction in HbA1c is associated with a:9
- 14% reduction in risk of myocardial infarction
- 37% reduction in risk of microvascular complications
- 21% reduction in overall deaths related to diabetes
*Rates per 1,000 person-years' follow-up, adjusted in Poisson regression model to white men aged 50 to 54 years at diagnosis of diabetes, and followed up for 7.5 to <12.5 years, termed “10 years” (n = 4,585).
INVOKANA is associated with body weight reduction as an additional benefit
Note: INVOKANA is not indicated for weight loss.
-crop1185x733.png?ver=3sWjlOEoZ0Pe-urQVcn1rg%3d%3d "image (1)")
Body weight change from baseline (LOCF) achieved in Phase III trials of Invokana in dual therapy7,16. Change in bodyweight from baseline was a prespecified secondary endpoint.
LOCF: last observation carried forward
